for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Illumina, Inc.

ILMN.O

Latest Trade

434.59USD

Change

-0.17(-0.04%)

Volume

1,023,602

Today's Range

431.38

 - 

436.69

52 Week Range

261.25

 - 

555.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
434.76
Open
436.69
Volume
1,023,602
3M AVG Volume
14.04
Today's High
436.69
Today's Low
431.38
52 Week High
555.77
52 Week Low
261.25
Shares Out (MIL)
146.70
Market Cap (MIL)
64,254.60
Forward P/E
73.92
Dividend (Yield %)
--

Next Event

Q3 2021 Illumina Inc Earnings Release

Latest Developments

More

Illumina Q2 Earnings Per Share $1.26

Illumina Files Action For Annulment Of European Commission’S Decision Asserting Jurisdiction To Review Grail Acquisition

Illumina Reports Q1 Non GAAP EPS $1.89

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Illumina, Inc.

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

Industry

Scientific & Technical Instr.

Contact Info

5200 Illumina Way

SAN DIEGO, CA

92122-4616

United States

+1.858.2024500

https://www.illumina.com

Executive Leadership

John Wendell Thompson

Independent Chairman of the Board

Francis A. deSouza

President, Chief Executive Officer, Director

Sam A. Samad

Chief Financial Officer

Robert Ragusa

Chief Operations Officer

Aimee L. Hoyt

Chief People Officer

Key Stats

2.83 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.3K

2019

3.5K

2020

3.2K

2021(E)

4.3K
EPS (USD)

2018

5.720

2019

6.570

2020

4.500

2021(E)

5.743
Price To Earnings (TTM)
84.16
Price To Sales (TTM)
16.20
Price To Book (MRQ)
12.35
Price To Cash Flow (TTM)
66.79
Total Debt To Equity (MRQ)
32.41
LT Debt To Equity (MRQ)
32.41
Return on Investment (TTM)
11.02
Return on Equity (TTM)
9.65

Latest News

Latest News

Illumina expects EU order to keep Grail a separate company

Illumina Inc expects an EU order to keep recently acquired Grail Inc as a separate company, the U.S. life sciences company said on Monday, hours after EU antitrust regulators warned of interim measures for closing the deal before their approval.

Illumina says it had expected EU hold order on Grail

U.S. life sciences company Illumina said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clearance of the deal.

CORRECTED-EU regulators plan interim measures against Illumina in Grail deal

EU antitrust regulators on Monday announced plans to impose interim measures against U.S. life sciences company Illumina for for closing its $8 billion cash-and-stock takeover of cancer detection test maker Grail deal before gaining approval.

U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail

Two Republican lawmakers on Thursday questioned the Federal Trade Commission's efforts to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging the regulator was not following a normal path in its work.

FTC urges judge to unwind $7.1 billion Illumina-Grail merger

The U.S. Federal Trade Commission on Tuesday said it seeks to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging it would harm innovation and boost prices.

Illumina-Grail deal heads to FTC trial, as EU weighs penalty

Lawyers for Illumina Inc are set to defend the life sciences company's $7.1 billion acquisition of Grail Inc at the U.S. Federal Trade Commission on Tuesday, as European antitrust regulators assail the company for closing the deal without first securing regulatory approval.

Illumina in EU antitrust sights over premature $8 billion Grail deal

U.S. life sciences company Illumina could face a hefty fine for completing its $8 billion cash-and-stock takeover of cancer detection test maker Grail without first securing EU antitrust approval.

EU regulators to investigate Illumina's completion of Grail deal

EU antitrust regulators on Friday opened an investigation into U.S. life sciences company Illumina's completion of its takeover of cancer detection test maker Grail deal despite an ongoing EU probe to see if this breached merger rules.

UPDATE 1-Illumina decision to close Grail deal disappointing, EU says

EU antitrust regulators on Thursday expressed disappointment at U.S. life sciences company Illumina's decision to complete its takeover of cancer detection test maker Grail and warned that gun-jumping could lead to hefty fines.

EU disappointed at Illumina decision to close Grail deal despite antitrust probe

EU antitrust regulators said on Thursday they were disappointed by U.S. life sciences company Illumina's decision to complete its takeover of cancer detection test maker Grail while an EU investigation is still ongoing.

Illumina closes $7.1 billion deal for cancer test maker Grail amid regulatory hurdles

Illumina Inc has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc, it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and the European Union antitrust regulators.

Illumina laments EU regulators' pause into Grail deal probe

U.S. life sciences company Illumina Inc on Thursday deplored EU antitrust regulators' decision to suspend temporarily their investigation into its planned purchase of Grail Inc, saying that the cancer test maker was crucial to patients.

EU regulators pause investigation into Illumina, Grail deal

EU antitrust regulators have temporarily halted their investigation into Illumina Inc's proposed purchase of cancer test maker Grail Inc as they wait for the U.S. life sciences company to provide requested data, an EU filing showed on Thursday.

FTC resists Illumina's push for more experts at merger trial

The Federal Trade Commission is resisting a bid from Illumina Inc to call two additional witnesses at the agency's upcoming antitrust trial, saying the request from the life sciences company is an effort to conduct a "trial-by-expert" proceeding.

Sidley, DLA Piper lobby for Illumina against FTC merger challenge

Illumina Inc ramped up its U.S. lobbying spend in Washington, D.C., in recent months, hiring law firms Sidley Austin and DLA Piper to advocate for the biotechnology company as it prepares to contest a Federal Trade Commission (FTC) antitrust complaint at trial in August,...

Illumina deal for Grail could hurt innovation, EU warns

U.S. life sciences company Illumina Inc's proposed acquisition of cancer test maker Grail Inc could curb innovation and competition, EU antitrust regulators warned Thursday as they opened a full-scale investigation.

EU antitrust regulators set July 22 deadline for Illumina, Grail deal

EU antitrust regulators will rule by July 22 whether to clear Illumina Inc's proposed $7.1 billion acquisition of cancer test maker Grail Inc, a European Commission filing showed on Thursday.

Exclusive-Illumina, Grail deal faces full-scale EU antitrust probe -sources

U.S. life sciences company Illumina Inc's proposed buy of cancer test maker Grail Inc faces a lengthy EU antitrust investigation if it does not offer hefty concessions this week, people familiar with the matter said on Tuesday.

EXCLUSIVE-Illumina, Grail deal faces full-scale EU antitrust probe -sources

U.S. life sciences company Illumina Inc's proposed buy of cancer test maker Grail Inc faces a lengthy EU antitrust investigation if it does not offer hefty concessions this week, people familiar with the matter said on Tuesday.

Illumina loses bid to escape 'Illuminox' TM dispute with Rakuten Medical

A federal judge in California has denied Illumina Inc's bid to toss biotech company Rakuten Medical Inc's lawsuit against it over Rakuten's use of the "Illuminox" name for a cancer treatment technology it has in development.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up